Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Agios Pharmaceuticals, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Agios Pharmaceuticals, Inc. (AGIO) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agios Pharmaceuticals, Inc. (“Agios” or “the Company”) (NASDAQ: AGIO). Investors who purchased Agios securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Agios has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On July 21, 2026, Agios issued a press release “announcing topline results from the Phase 2 trial of tebapivat, an oral pyruvate kinase (PK) activator, in patients aged 16 years or older with sickle cell disease.” The press release disclosed that “[t]he trial did not demonstrate the level of differentiation required to support continued development” and “therefore, Agios has decided not to advance tebapivat in sickle cell disease.” Following this news, Agios’s stock price dropped $2.70 per share, or 6.74%, to close at $37.36 per share on July 21, 2026.
What Should Agios Pharmaceuticals, Inc. (AGIO) Investors Do?
If you are aware of any facts relating to this investigation or purchased Agios securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Is Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”